Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Optomed Oyj (OPTOMED.HE)
Oulu, FI
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.77% | +2.15% | -29.83% | -45.84% | -60.92% | -57.41% | -60.63% | -57.19% | -85.12% | -64.76% | -64.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | -1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+13.7% Q1'26: -16.7% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-17.2% Q1'26: +34.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-26.6% Q1'26: -48.7% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-35.4% Q1'26: -40.9% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%-34.3% Q1'26: -30.8% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+6.1% Q1'26: +5.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-1.00× Q1'26: -0.89× (vs Q1'25)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.98M
est: 15.00M (-0.2%)
|
13.01M
est: 13.01M (+0.0%)
|
14.85M
est: 14.88M (-0.2%)
|
14.66M
est: 14.69M (-0.2%)
|
15.10M
est: 14.71M (+2.7%)
|
15.04M
est: 15.02M (+0.1%)
|
17.10M
est: 17.10M (0.0%)
|
17.96M
17.80M – 18.19M
+5.0% YoY
|
21.39M
20.01M – 22.47M
+19.1% YoY
|
26.57M
26.19M – 26.95M
+24.2% YoY
|
29.15M
28.01M – 30.13M
+9.7% YoY
|
41.60M
39.97M – 42.99M
+42.7% YoY
|
| EBITDA |
-1.17M
est: -2.24M (+47.5%)
|
-281.0K
est: -1.94M (+85.5%)
|
-2.97M
est: -2.22M (-34.0%)
|
-4.23M
est: -2.19M (-93.2%)
|
-1.30M
est: -2.74M (+52.4%)
|
-2.24M
est: -2.79M (+19.8%)
|
-3.53M
est: -3.18M (-11.0%)
|
-3.34M
-3.38M – -3.31M
-5.0% YoY
|
-3.98M
-4.18M – -3.72M
-19.1% YoY
|
-4.94M
-5.01M – -4.87M
-24.2% YoY
|
-5.42M
-5.61M – -5.21M
-9.7% YoY
|
-7.74M
-8.00M – -7.44M
-42.7% YoY
|
| EBIT |
-2.58M
est: -4.17M (+38.1%)
|
-3.08M
est: -3.62M (+15.0%)
|
-4.23M
est: -4.14M (-2.1%)
|
-5.44M
est: -4.08M (-33.1%)
|
-3.50M
est: -4.58M (+23.6%)
|
-4.74M
est: -4.67M (-1.4%)
|
-6.05M
est: -5.32M (-13.7%)
|
-5.59M
-5.66M – -5.54M
-5.0% YoY
|
-6.65M
-6.99M – -6.23M
-19.1% YoY
|
-8.27M
-8.39M – -8.15M
-24.2% YoY
|
-9.07M
-9.37M – -8.71M
-9.7% YoY
|
-12.94M
-13.38M – -12.43M
-42.7% YoY
|
| Net Income |
-2.88M
est: -7.28M (+60.5%)
|
-3.18M
est: -4.48M (+29.1%)
|
-4.25M
est: -5.70M (+25.4%)
|
-5.47M
est: -6.91M (+20.8%)
|
-4.44M
est: -5.44M (+18.3%)
|
-5.45M
est: -5.79M (+5.9%)
|
-6.64M
est: -6.16M (-7.8%)
|
-3.31M
-3.46M – -3.15M
+46.3% YoY
|
-2.20M
-2.26M – -2.05M
+33.5% YoY
|
-50.0K
-3.57M – 1.79M
+97.7% YoY
|
-124.9K
-130.3K – -118.5K
-149.8% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
993.0K
est: 2.29M (-56.7%)
|
1.14M
est: 1.99M (-42.9%)
|
1.54M
est: 2.27M (-32.3%)
|
1.55M
est: 2.25M (-31.0%)
|
3.14M
est: 2.69M (+17.0%)
|
3.91M
est: 2.74M (+42.3%)
|
4.04M
est: 3.12M (+29.3%)
|
3.28M
3.25M – 3.32M
+5.0% YoY
|
3.91M
3.66M – 4.11M
+19.1% YoY
|
4.86M
4.79M – 4.93M
+24.2% YoY
|
5.33M
5.12M – 5.51M
+9.7% YoY
|
7.60M
7.30M – 7.86M
+42.7% YoY
|
| EPS |
-0.32
est: -0.39 (+17.9%)
|
-0.24
est: -0.24 (+0.0%)
|
-0.32
est: -0.31 (-4.9%)
|
-0.37
est: -0.37 (+0.0%)
|
-0.27
est: -0.28 (+2.0%)
|
-0.29
est: -0.29 (+0.9%)
|
-0.34
est: -0.33 (-3.8%)
|
-0.17
-0.17 – -0.16
+48.8% YoY
|
-0.11
-0.11 – -0.10
+34.8% YoY
|
-0.05
-0.18 – 0.09
+58.8% YoY
|
-0.01
-0.01 – -0.01
+86.0% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Juho Himberg | Chief Executive Officer | 267.0K | male |
| Seppo Henrik Kopsala | Founder | 156.0K | male |
| Sakari Knuutti | Chief Financial Officer, Chief Legal Officer & Secretary of the Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OPTOMED.HE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
